Growth reduction among primary schoolchildren with light trichuriasis in Malaysia treated with albendazole

Area of Science:

• Tropical medicine
• Pediatric helminthology
• Nutritional immunology

Background:

• Trichuriasis, a common soil-transmitted helminth infection, affects millions of schoolchildren globally.
• Subclinical infections can impact child development, including growth and inflammatory markers.
• Albendazole is a primary anthelmintic used for treating trichuriasis.

Purpose of the Study:

• To investigate the impact of albendazole on growth and TNF-alpha levels in asymptomatic schoolchildren with trichuriasis.
• To assess the efficacy of a standard albendazole regimen in this specific population.

Main Methods:

• A randomized, placebo-controlled trial was conducted with 37 asymptomatic schoolchildren (aged 6-7 years) in Malaysia.
• Participants received either albendazole (400 mg daily for 2 days) or a placebo.
• Anthropometric measurements and urinary TNF-alpha levels were assessed at baseline and at 3, 6, and 12 months post-treatment.

Main Results:

• The placebo group exhibited a significantly greater increase in height compared to the albendazole group (p = 0.04) at 6 months.
• No significant differences in urinary TNF-alpha levels were observed between the groups.
• No significant changes in TNF-alpha levels were found from baseline to 1 month post-treatment.

Conclusions:

• Albendazole treatment for light to moderate trichuriasis in asymptomatic schoolchildren was associated with a temporary delay in growth rate.
• The drug did not significantly alter TNF-alpha levels, suggesting inflammation is not the primary mechanism for the observed growth effect.
• Further research is warranted to elucidate the etiology of this growth delay and its long-term implications.